Barinthus Total Stockholder Equity from 2010 to 2024
| BRNS Stock | 0.89 0.10 10.10% |
Total Stockholder Equity | First Reported 2010-12-31 | Previous Quarter 186.8 M | Current Value 136.9 M | Quarterly Volatility 107.5 M |
Check Barinthus Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Barinthus Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.7 M, Interest Expense of 26.6 K or Total Revenue of 761.9 K, as well as many indicators such as Price To Sales Ratio of 168, Dividend Yield of 0.0 or PTB Ratio of 0.54. Barinthus financial statements analysis is a perfect complement when working with Barinthus Biotherapeutics Valuation or Volatility modules.
Barinthus | Total Stockholder Equity |
Latest Barinthus Biotherapeutics' Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of Barinthus Biotherapeutics plc over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Barinthus Biotherapeutics' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Barinthus Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
Barinthus Total Stockholder Equity Regression Statistics
| Arithmetic Mean | 37,126,074 | |
| Coefficient Of Variation | 289.69 | |
| Mean Deviation | 89,353,727 | |
| Median | (22,446,314) | |
| Standard Deviation | 107,549,652 | |
| Sample Variance | 11566.9T | |
| Range | 289.4M | |
| R-Value | 0.71 | |
| Mean Square Error | 6255.9T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | 16,967,495 | |
| Total Sum of Squares | 161937T |
Barinthus Total Stockholder Equity History
About Barinthus Biotherapeutics Financial Statements
Barinthus Biotherapeutics shareholders use historical fundamental indicators, such as Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Barinthus Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Barinthus Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Barinthus Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 186.8 M | 136.9 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Barinthus Stock Analysis
When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.